Bayer Stock

€27.93

1.72% yesterday

Xetra, Aug 28, 05:44 pm CET

ISIN

DE000BAY0017

Symbol

BAYN

Index

DAX, DAX Kursindex, EURO STOXX 50

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Bayer Stock price

€27.93

-27.11 49.26% 5Y

Xetra, Closing price Thu, Aug 28 2025

-0.49 1.72%

ISIN

DE000BAY0017

Symbol

BAYN

Index

DAX, DAX Kursindex, EURO STOXX 50

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

€27.9b

Enterprise Value

€60.8b

Net debt

€32.9b

Cash

€5.5b

Shares outstanding

982.4m

Valuation (TTM | estimate)

P/E

negative | 6.0

P/S

0.6 | 0.6

EV/Sales

1.3 | 1.3

EV/FCF

13.3

P/B

0.9

Dividends

DPS

€0.11

Yield 1Y | 5Y

0.4% | 2.7%

Growth 1Y | 5Y

0.0% | -47.7%

Payout 1Y | 3Y

-4.2% | -191.2%

Increased

0 Years

Financials (TTM | estimate)

Revenue

€46.2b | €46.7b

EBITDA

€6.6b | €9.5b

EBIT

€-1.4b | €5.6b

Net Income

€-3.4b | €4.6b

Free Cash Flow

€4.6b

Growth (TTM | estimate)

Revenue

-2.0% | 0.3%

EBITDA

-32.8% | -25.8%

EBIT

-161.1% | 39.9%

Net Income

-170.0% | 281.8%

Free Cash Flow

-19.3%

Financial Health

Equity Ratio

28.8%

Return on Equity

-8.0%

ROCE

-1.8%

ROIC

-1.8%

Debt/Equity

1.3

EPS

€-3.5

FCF per Share

€4.7

Short interest

Employees

91k

Rev per Employee

€510.0k

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Bayer Stock Analysis

Unlock Scores for Free

28 Analysts have issued a Bayer forecast:

13x Buy

46%

15x Hold

54%

More details on Analyst Estimates Including Price Targets

28 Analysts have issued a Bayer forecast:

Buy

46%

Hold

54%

Analyst Estimates with Stock Price Targets

Financial data from Bayer

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '25		+/- %
Revenue	46,174 46,174	2% 2% 100%
- Direct Costs	20,802 20,802	5% 5% 45%
Gross Profit	25,372 25,372	7% 7% 55%
- Selling and Administrative Expenses	15,312 15,312	2% 2% 33%
- Research and Development Expense	6,150 6,150	12% 12% 13%
EBITDA	6,623 6,623	33% 33% 14%
- Depreciation and Amortization	7,974 7,974	4% 4% 17%
EBIT (Operating Income) EBIT	-1,351 -1,351	161% 161% -3%
Net Profit	-3,418 -3,418	170% 170% -7%

In millions EUR.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Bayer Stock News

Neutral

GlobeNewsWire

●

7 days ago

Bayer's E.L.Y. Wins “AI-based AgTech Solution of the Year” In 2025 AgTech Breakthrough Awards Program

Annual Awards Program Recognizes Innovation in Agricultural & Food Technologies Around the Globe Annual Awards Program Recognizes Innovation in Agricultural & Food Technologies Around the Globe

Positive

Reuters

●

10 days ago

Bayer settles Sky Valley cases over chemical PCB

Bayer said on Monday its Monsanto unit reached agreements in principle with more than 200 plaintiffs to resolve the so-called Sky Valley Education Center product liability cases related to the chemical PCB.

AD HOC NEWS

●

11 days ago

USA: Bayer kann viele PCB-Klagen wohl bald beilegen - Aktienkurs legt etwas zu

Bayer DE000BAY0017 kann einen wesentlichen Teil der US-Rechtsstreitigkeiten rund um die schon seit Jahrzehnten verbotene Umweltchemikalie PCB wohl schon bald hinter sich lassen.

More Bayer News

Company Profile

Bayer AG engages in the development, manufacture and distribution of products in the areas of health care, nutrition and high-tech materials. It operates through the following segments: Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment engages in the development, production and marketing of prescription products for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology and ophthalmology; diagnostic imaging equipment and the necessary contrast agents. The Consumer Health segment manufactures and markets products in the dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories. The CropScience segment includes seeds and plant traits, crop protection and nonagricultural pest control. The Animal Health segment offers prescription and nonprescription veterinary products. The Covestro segment provides raw materials for polyurethanes; polycarbonate granules and sheets; raw materials for coatings, adhesives and sealants; and by-products of polyether production and of chlorine production and use. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.

Head office	Germany
CEO	William Anderson
Employees	90,587
Founded	1863
Website	www.bayer.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now